Wegovy helps people sustain weight-loss successes for up to 4 years, study finds
A new examination of research published last year found that people maintained an average 10% weight loss over four years while taking Wegovy, Novo Nordisk's obesity drug. The new research, funded by the drug maker, was presented Tuesday at the European Congress on Obesity in Venice, Italy, and published in the journal Nature.